Genmab announced that its partner Janssen Biotech will launch three novel studies to investigate the effect of Darzalex (daratumumab) in patients with multiple myeloma. The Danish company says its agreement grants Janssen — based in Titusville, New Jersey — authorization to exclusively develop, produce and market Darzalex. The studies,…
The non-profit cancer-therapy consulting group Patient Power is hailing a District of Columbia law that established patient co-pay ceilings on specialty medications for diseases like multiple myeloma. Co-pays are a common feature of American health insurance plans. The term refers to a patient paying part of the cost of prescriptions or healthcare…
The International Myeloma Foundation (IMF) says it is deeply worried that the American Health Care Act (AHCA) — which narrowly passed the U.S. House of Representatives on May 4 and now goes to the Senate for consideration — will have serious consequences for multiple myeloma patients and others with pre-existing…
A new documentary, “200 Miles,” tells the inspiring story of ultra-marathoner Eric Gelber’s determination to complete 33 loops of New York’s Central Park to honor a friend who died of multiple myeloma. Gelber, who became a multiple myeloma advocate when his friend Anita Sorrell was battling the cancer before her…
Switzerland’s Agency for Therapeutic Products (Swissmedic) has awarded PharmaMar’s Aplidin orphan drug status to treat patients with multiple myeloma, following a similar designation by the U.S. Food and Drug Administration (FDA). This decision was also supported by data regarding the drug’s efficacy, safety and quality, and well as the prevalence of multiple…
Israel’s One World Cannabis (OWC) says it’s moving forward to mouse models to test its unique formula of cannabinoid-based therapies targeting cancer cells. This decision followed promising results from preclinical in vitro studies. “After in-depth and extensive review and assessment of the study’s results accumulated so far, OWC’s research committee determined that the…
Janssen’s Darzalex (daratumumab) received full approval by the European Commission (EC) for use in treating adult patients with multiple myeloma who have received at least one prior therapy. The EC approved Darzalex for use not only as a single therapy, but in combination with Revlimid (lenalidomide) and dexamethasone, or Velcade…
GlycoMimetics’ GMI-1271 restored the punch of the myeloma treatment Velcade (bortezomib) in mice, which should rekindle hope in patients who failed to respond to Velcade, a study reports. GMI-1271, which is being tested in clinical trials, blocks E-selectin, an adhesion molecule associated with aggressive myeloma and resistance to Velcade. Another…
Multiple myeloma patients who received at least three prior lines of therapy and whose cancer expresses the CD33 molecule may enroll in the recently opened Phase 1 clinical trial at Baylor Scott & White Research Institute, part of Baylor Health Care, in Dallas, Texas. The open-label, single-arm trial (NCT02998047)…
Janssen Biotech will discuss at a Chicago cancer conference the effectiveness of new multiple myeloma treatment combinations that include its therapy Darzalex (daratumumab). The United States and European Union approved some combinations of Darzalex and other therapies in 2016, but Janssen wanted to evaluate additional combinations. Janssen will present…
Get regular updates to your inbox.